The U.S. Food and Drug Administration has approved Jardiance 10 mg and 25 mg tablets to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes, Boehringer Ingelheim and Eli Lilly and Company announced. “With this latest FDA decision, Jardiance is now approved to lower A1c along with diet and exercise in children 10 years and older with type 2 diabetes. This decision brings us one step closer in our efforts to improve outcomes for this population and supports our larger commitment to advance treatment options for people living with a range of cardiometabolic conditions,” said Leonard Glass, M.D., F.A.C.E., senior vice president, Diabetes & Obesity Global Medical Affairs, Lilly.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on LLY:
- Dice Therapeutics downgraded to Market Perform from Outperform at TD Cowen
- Dice Therapeutics downgraded to Market Perform from Outperform at SVB Securities
- Dice Therapeutics downgraded to Neutral from Buy at Guggenheim
- Dice Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Dice Therapeutics downgraded to Hold from Buy at Stifel